A Study With Imlifidase in Anti-GBM Disease
NCT05679401
Active Not Recruiting
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: UCLA Medical Center Plaza, Los Angeles, California +47 locations
Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Register for Updates
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
NCT02406222
Active Not Recruiting
This study is determining whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression free survival in patients with relapsed refractory myeloma (RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1 basis to receive CPD or Pd. Treatment will be continued until disease progression or unacceptable toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Belfast Health & Social Care Trust, Belfast, Not set +20 locations
Conditions: Multiple Myeloma
Register for Updates
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144
Active Not Recruiting
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Gender:
ALL
Ages:
Between 3 years and 25 years
Trial Updated:
11/18/2024
Locations: Children's Hospital of Alabama ( Site 0023), Birmingham, Alabama +92 locations
Conditions: Hodgkin Lymphoma
Register for Updates
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT02626455
Terminated
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine \[R-B\] and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone \[R-CHOP\]) is effective and safe, compared with placebo in combination with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have received at least one, but at most three, lines of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Ironwood Physicians P.C. DBA Ironwood Cancer & Res. Ctr., Chandler, Arizona +200 locations
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies
NCT05658640
Recruiting
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol D is a phase I/II trial evaluating the safety and efficacy of trametinib in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the RAS-RAF-MAPK pathway.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
11/07/2024
Locations: St. Anna Kinderspital, Vienna, Not set +35 locations
Conditions: Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Register for Updates
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
NCT04745832
Terminated
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: The Oncology Institute of Hope and Innovation, Tucson, Arizona +140 locations
Conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Register for Updates
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
NCT03009058
Terminated
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type. The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, Not set +3 locations
Conditions: Metastatic Cancer
Register for Updates
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
NCT05993299
Active Not Recruiting
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
09/30/2024
Locations: City of Hope National Medical Center, Duarte, California +37 locations
Conditions: Neoplasms
Register for Updates
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092
Active Not Recruiting
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/06/2024
Locations: MorphoSys Research Site, Daphne, Alabama +306 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT03498716
Terminated
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: John Muir Health Clinical Research Center, Concord, California +363 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
NCT03493854
Completed
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Maryland Oncology Hematology, Rockville, Maryland +106 locations
Conditions: Early Breast Cancer
Register for Updates
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907
Recruiting
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2024
Locations: Queensland Children's Hospital, Brisbane, Not set +127 locations
Conditions: Rhabdomyosarcoma
Register for Updates